ctDNA Predicts Pain Response in a Multi-Institutional Phase II Trial of Palliative Radiation, Palbociclib and Hormone Therapy in Metastatic Breast Cancer

被引：0

作者：

Torres, M. ^{[1
]}

Friend, S. ^{[2
]}

Niemierko, A. ^{[3
]}

Lin, J. Y. ^{[1
]}

Iafrate, A. ^{[3
]}

Xiao, C. ^{[4
]}

Kahn, S. T. ^{[5
]}

Godette, K. D. ^{[6
]}

Hanasoge, S. ^{[5
]}

Yu, D. S. ^{[6
]}

Eng, T. Y. ^{[5
]}

Cheney, M. D. ^{[7
]}

Wiggers, N. ^{[8
]}

Pippas, A. ^{[9
]}

Goginini, K.

Meisel, J. ^{[10
]}

Schuster, D. M. ^{[11
]}

Bardia, A. ^{[12
]}

Miller, A. H. ^{[13
]}

Felger, J.

Switchenko, J. ^{[14
]}

Zelnak, A. ^{[15
]}

Kalinsky, K. ^{[16
]}

Daniels, T. ^{[2
]}

Medford, A. ^{[3
]}

Bhave, M. ^{[17
]}

机构：

[1] Emory Univ, Glenn Family Breast Ctr, Winship Canc Inst, Atlanta, GA USA

[2] Emory Univ, Sch Med, Atlanta, GA USA

[3] Massachusetts Gen Hosp, Boston, MA USA

[4] Emory Univ, Nell Hodgson Woodruff Sch Nursing, Atlanta, GA USA

[5] Emory Univ, Dept Radiat Oncol, Winship Canc Inst, Atlanta, GA USA

[6] Emory Univ, Winship Canc Inst, Dept Radiat Oncol, Atlanta, GA USA

[7] Spectrum Healthcare Partners, Portland, ME USA

[8] Northside Hosp, Atlanta, GA USA

[9] Piedmont Columbus Reg, John B. Amos Canc Ctr, Columbus, GA USA

[10] Emory Univ, Winship Canc Inst, Dept Med Oncol, Atlanta, GA USA

[11] Emory Univ, Dept Radiol & Imaging Sci, Atlanta, GA USA

[12] UCLA, Los Angeles, CA USA

[13] Emory Univ, Sch Medi, Dept Psychiat & Behav Sci, Atlanta, GA USA

[14] Emory Univ, Atlanta, GA USA

[15] Northside Hosp, Atlanta Canc Care, Atlanta, GA USA

[16] Emory Winship Canc Inst, Atlanta, GA USA

[17] Emory Univ, Sch Med, Dept Hematol & Med Oncol, Atlanta, GA USA

来源：

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2024年 / 120卷 / 02期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1037

引用

页码：S164 / S164

页数：1

共 50 条

[11] Hypofractionated High-Dose Radiation Therapy for Prostate Cancer: Long-Term Results of a Multi-Institutional Phase II Trial
Fonteyne, Valerie
Soete, Guy
Arcangeli, Stefano
De Neve, Wilfried
Rappe, Bernard
Storme, Guy
Strigari, Lidia
Arcangeli, Giorgio
De Meerleer, Gert
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (04): : E483 - E490
[12] IFOSFAMIDE PLUS DOXORUBICIN IN METASTATIC ADULT SARCOMAS - A MULTI-INSTITUTIONAL PHASE-II TRIAL
LOEHRER, PJ
SLEDGE, GW
NICAISE, C
USAKEWICZ, J
HAINSWORTH, JD
MARTELO, OJ
OMURA, G
BRAUN, TJ
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (11) : 1655 - 1659
[13] A multi-institutional phase II trial of pazopanib monotherapy in advanced anaplastic thyroid cancer
Bible, Keith Christopher
Suman, VeraJean
Menefee, Michael E.
Smallridge, Robert C.
Molina, Julian R.
Maples, William James
Karlin, Nina J.
Traynor, Anne M.
Kumar, Priya
Goh, Boon C.
Lim, Wan-Teck
Bossou, Ayoko R.
Isham, Crescent R.
Webster, Kevin P.
Kukla, Andrea K.
Bieber, Carolyn
Burton, Jill K.
Harris, Pamela Jo
Erlichman, Charles
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[14] Excellent acute toxicity outcomes with proton therapy for partial breast irradiation in early stage breast cancer: Initial results of a multi-institutional phase II trial
Choi, J. Isabelle
Chang, Andrew L.
CANCER RESEARCH, 2018, 78 (04)
[15] A single arm phase II study of palbociclib in combination with tamoxifen as first line therapy for metastatic hormone receptor positive breast cancer
Danciu, Oana C.
Hoskins, Kent
Tamkus, Deimante
Truica, Cristina
Blaes, Anne
Green, Lauren
Liu, Li
Toppmeyer, Deborah
Wisinski, Kari
CANCER RESEARCH, 2018, 78 (04)
[16] Phase II trial of bicalutamide in combination with palbociclib for the treatment of androgen receptor (+) metastatic breast cancer.
Gucalp, Ayca
Boyle, Leigh Ann
Alano, Tina
Arumov, Artavazd
Gounder, Mrinal M.
Patil, Sujata
Feigin, Kimberly
Edelweiss, Marcia
D'Andrea, Gabriella
Bromberg, Jacqueline
Goldfarb, Shari Beth
Ligresti, Louise
Wong, Serena Tsan-Lai
Traina, Tiffany A.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[17] Phase II trial of palbociclib with fulvestrant in individuals with hormone receptorpositive, HER2-negative metastatic breast cancer with disease progression after palbociclib with an aromatase inhibitor
Tao, Jessica J.
Blackford, Amanda L.
Nunes, Raquel
Truica, Cristina I.
Mahosky, Justin
Jones, Mary Kate
Leasure, Nick C.
Cescon, Terrence
Christou, Antonios
Werner, Jeanine L.
Couzi, Rima
Smith, Karen L.
Santa-Maria, Cesar Augusto
Wolff, Antonio C.
Stearns, Vered
CANCER RESEARCH, 2023, 83 (05)
[18] Exploration of ctDNA Dynamics in the PACE Trial: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for HR+/HER2-Metastatic Breast Cancer
Jeselsohn, Rinath
Fu, Jingxin
Ren, Yue
Mahtani, Reshma
Ma, Cynthia
DeMichele, Angela
Cristofanilli, Massimo
Meisel, Jane
Miller, Kathy
Abdou, Yara
Riley, Elizabeth
Qamar, Rubina
Sharma, Priyanka
Reid, Sonya
Ko, Naomi
Liu, Yuan
Burstein, Harold
DeMeo, Michelle
Tolaney, Sara
Mayer, Erica
CANCER RESEARCH, 2024, 84 (09)
[19] A single-arm phase II trial of palbociclib in combination with tamoxifen as first-line therapy for metastatic hormone receptor-positive breast cancer.
Danciu, Oana Cristina
Hoskins, Kent
Truica, Cristina I.
Blaes, Anne Hudson
Tamkus, Deimante
Rana, Jatin
Tandra, Pavankumar
Green, Lauren
Yu, Menggang
Zhao, Qianqian
Toppmeyer, Deborah
O'Regan, Ruth
Wisinski, Kari Braun
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[20] Preliminary results of a multi-institutional phase II trial of proton beam therapy for organ confined prostate cancer in Japan
Nihei, K.
Ogino, T.
Onozawa, M.
Murayama, S.
Fuji, H.
Murakami, M.
Hishikawa, Y.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : S291 - S291

← 1 2 3 4 5 →